Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 1 · 25%High 0 · 0%

Anti‐PD1 monoclonal antibodies vs anti‐CTLA4 monoclonal antibodies

Toxicity (≥ G3) · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies may leads to lower toxicity (≥ G3) compared with anti‐CTLA4 monoclonal antibodies (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 0.7 [0.54, 0.91]
1465 participants
Low

Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies

Toxicity (≥ G3) · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies with showed no clear difference in toxicity (≥ G3) compared with without anti‐PD1 monoclonal antibodies (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.57 [0.85, 2.92]
764 participants
Low

Anti‐PD1 monoclonal antibodies vs chemotherapy alone

Toxicity (≥ G3) · people with cutaneous melanoma

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
0.55 [0.31, 0.97]
1360 participants
Low

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Toxicity (≥ G3) · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.69 [1.19, 2.42]
1142 participants
Moderate